To evaluate prostate cancer (PCa) detection after repeated negative saturation biopsy, 75 patients, aged 53-78 years, underwent transurethral resection of prostate (TURP) because of persistent suspicion of cancer; median PSA was 11.8 ng ml À1 and 58 men complained lower urinary tract symptoms (LUTS). In 12 (16%) and 3 (4%) men a T1a and T1b PCa was found with median PSA and Gleason score equal to 14.2 vs 23.6 ng ml À1 and 5.6 vs 7 ng ml À1 . In case of persistent suspicion of PCa after repeated negative saturation biopsy, TURP may be proposed, aside from the coexistence of LUTS, to rule out a PCa, in younger patients with high PSA values (X20 ng ml
Introduction
The widespread use of PSA in clinical practice has led to an increased diagnosis of prostate cancer (PCa), although the specificity of PSA levels o10 ng ml À1 is rather poor. 1 To improve the diagnostic accuracy, some determinants of PSA kinetics (free-to-total PSA ratio, PSA density, PSA velocity and PSA doubling time) along with extended biopsy protocols have been introduced. 2 However, despite multiple negative biopsies, some patients still remain with a suspicion of harbouring a cancer. Recently, in selected cases, a transurethral resection of prostate (TURP) has been proposed as an additional diagnostic tool, besides the coexistence of lower urinary tract symptoms (LUTS), for detecting PCa. 3 In this study, the incidence of PCa in 75 patients, who underwent TURP after a second negative saturation prostate biopsy (SPBx), is reported.
Materials and methods

From June 2005 to February 2008, 75 consecutive
Caucasians patients aged between 53 and 78 years (median 65.4) with negative digital rectal examination and persistent suspicion of PCa after a second transrectal ultrasound-guided SPBx underwent TURP; the procedure was performed 4 months (median) (range: 3-6) after SPBx and 12 months (median) (range: 6-16) after the first extended prostate biopsy. The patients were enroled in a case-finding protocol for PCa 4 and indications for TURP were PSA410 ng ml À1 ; PSA included between 4.1 and 10 or 2.6 and 4 ng ml À1 with free/total PSA p25 and p20%, respectively. 4 All men had previously underwent a second negative SPBx following the same clinical indications (patients with high-grade prostatic intraepithelial neoplasia or atypical small acinar proliferation did not meet inclusion criteria); a median of 28 (range: 26-38) cores were taken in the posterior zone including 3.5 (median; range: 3-5) cores in the transitional and anterior zones. The median PSA was 11.8 ng ml À1 (range: 2.7-36) and only 58 (77.4%) patients had abnormal International Prostate Symptom Score (IPSS). Preoperatively, uroflowmetry, prostate, kidney and bladder ultrasound, post-voiding residual urine measurement and IPSS were evaluated (Table 1) .
Surgery was performed under epidural anaesthesia using an Olympus resectoscope 26 Ch; prostate fragments were weighted and carefully examined by three dedicated pathologists (FF, AG and GG).
All patients signed an informed consent form, which, in addition to the clinical risk of TURP, explicitly reported an additional set of SPBx as an alternative option to surgery.
Results
The mean operative time was 50 min (range: 30-70); only 2/75 (2.7%) patients required blood transfusion and median hospital stay was 4 days (range: 3-7). In all cases, the postoperative course was uneventful.
On average, 46 g of tissue (range: 11-70) were removed by TURP; PCa was found in 15/75 (20%) patients with median PSA and the Gleason score (GS) equal to 15.7 ng ml À1 (range: 6.2-27) and 5.9 (GS 4: 1 case; GS 5: 2 cases; GS 6: 9 cases; and GS 7: 3 cases). The remaining 60 (80%) patients had a diagnosis of benign pathology (BPH and/or prostatitis) with a median PSA of 10.8 ng ml
À1
. Three months after TURP, the patients with benign histological findings had a median IPSS of 5 (range: 0-15), no post-voiding residual and Q max X15 ml s À1 (range: 15-37); 3 (5%) men referred urgency.
Clinical stage of the cancers diagnosed by TURP was T1a in 12 (16%) and T1b in 3 (4%) patients, with median PSA of 14.2 and 23.6 ng ml
; of these men, 10/15 (66.7%) complained LUTS preoperatively. The three patients with clinical stage T1b PCa underwent radical prostatectomy (RP) with standard pelvic lymphadenectomy; final pathology showed one pT3aN0, one pT2cN0 and one pT2bN0 PCa with negative surgical margins and GS 7 (3 þ 4; 4 þ 3; and 3 þ 4, respectively) ( Table 2 ). At 5 months (median) (range: 4-7) after RP, all patients recovered urinary continence. At 24 months (range: 6-30) after TURP, in the patients with clinical stage T1a PCa enroled in a watchful waiting protocol (no patients were lost during follow-up), median PSA was 0.9 ng ml À1 (range: 0.4-1.3), whereas median PSA in the patients with benign histological findings was 1.0 ng ml À1 (0.8-3.4).
Discussion
Transrectal ultrasound-guided sextant prostate biopsy, proposed by Hodge et al. 5 in 1989, was considered the gold standard in diagnosing PCa until it was shown that about 15-20% of clinical significant cancers were missed, 6 leading to the necessity of repeating several biopsy sets in a consistent number of patients. Until now, an extended transrectal ultrasound-guided biopsy scheme with an increased number of cores on the peripheral portion and on the lateral margins of the gland is the only suitable method to improve the detection rate of PCa; 7 however, the SPBx (that is, X24 cores) does not improve cancer detection rate in comparison with 12 or 18 cores biopsy as an initial prostate biopsy strategy. 8, 9 Some parameters (time elapsed from the previous biopsy, previous high-grade prostatic intraepithelial neoplasia or atypical small acinar proliferation) have been proposed to predict positive repeat biopsy for cancer, 10, 11 
14 and Singh et al. 15 showed an incidence of PCa of 31.9 and 14% in 241 and 99 patients, respectively, after a second 12 cores biopsy.
SPBx has been recommended in case of repeat biopsy for increasing PCa detection rate: Fleshner and Klotz 16 reported a PCa incidence of 13% in 37 selected patients; Walz et al. 17 showed a PCa incidence of 41% in 161 patients; Rabets et al. 18 reported 41 and 24% of PCa in 116 men previously submitted to 6 and 10 cores biopsy schemes, respectively; and Rodriguez Alonso et al. 19 and Jones et al. 20 reported 40.8 and 33% of cancer, respectively. In our experience, 9 PCa detection rate of 22.6% in 75 patients submitted to SPBx after an initial negative extended biopsy was found.
A transition zone sampling is recommended at repeat biopsy, although the cancer detection rate in this region is very low, ranging from 1.8%, 13, 22 3.7% 21 up to 5.3%. 23 However, a consistent number of PCa, not found by biopsy, are subsequently diagnosed by TURP or open adenomectomy. For this reason, after multiple negative biopsy series, some authors have suggested to perform a TURP, even in men not complaining LUTS: Radhakrishnan et al. 24 Zigeuner et al. 25 and Puppo et al. 3 reported a PCa detection after TURP of 21, 7.9 and 42.8%, respectively. Recently, van Renterghem et al. 26 in 82 patients with minor LUTS but elevated PSA levels evaluated the clinical benefits of TURP by assessing its effect on IPSS, PSA levels and cancer detection rate: they reported an incidental PCa in 9.8% of cases, whereas PSA levels and IPSS score in patients with BPH decreased to 1.1 and 1.5 ng ml
À1
, respectively. PCa diagnosed by TURP frequently originate in the anterior prostate is organ-confined with a GS p6, suggesting that tumours located in the transition zone have a less aggressive phenotype than those found in the peripheral zone; 27 PSA values evaluated before and after TURP and GS are considered significant predictors of residual cancer at RP. 28 In our experience, PCa detection rate in patients submitted to TURP after a second negative SPBx was 20% (15 of 75 patients), but only 3 (4%) men with high PSA values (median 23.6 ng ml À1 had a clinical relevant (i.e., clinical stage T1b) PCa worthy of definitive treatment. PCa detection by TURP after SPBx P Pepe et al
Transurethral resection of prostate allowed to distinguish the 12 patients with T1a PCa, who were enroled in a watchful waiting protocol, from patients with T1b cancer who underwent RP; on the contrary, in presence of one or more positive biopsy cores detected only in the transition zone during prostate biopsy it is a difficult task to advice the best management because RP could be an overtreatment. Although TURP could underestimate the burden of the disease considering that PCa is reported in 12% of the samples taken from both the peripheral and transition parenchyma on extended biopsy; 13 in our series PSA was stable (median 0.9 ng ml À1 ) after a median follow-up of 2 years in all patients with clinical stage T1a, suggesting that cancer was localized exclusively in the removed parenchyma of the transition zone. At the same time, in patients with benign histological findings, a significant reduction of PSA values (1.0 ng ml À1 ; range: 0.8-1.4) was observed allowing to distinguish patients with stable PSA and normal digital rectal examination from those with increasing PSA eligible for a repeat SPBx.
In conclusion, although TURP detected only a negligible proportion of clinically significant cancer in case of persistent suspicion of PCa after negative repeated SPBx, TURP could be proposed as part of the diagnostic procedure to rule out PCa, besides LUTS, especially in patients with high PSA values (X20 ng ml
) and life expectancy 410 years advising the patients on the postoperative consequences (that is, retrograde ejaculation) of a procedure that, in a significant proportion of cases, may end up 'curing' only an elevated PSA value. PCa detection by TURP after SPBx P Pepe et al
